The NFκB activity is constitutively increased in aggressive ovarian cancers, and inhibition of NFκB signaling suppresses angiogenesis and tumorigenicity of ovarian cancer cells and increases their sensitivity to chemotherapy and apoptosis [37,38,39,40]. This evidence concerns the gene NFKB1 and ovarian carcinoma.